CYAD
Income statement / Annual
Last year (2024), Celyad Oncology S.A.'s total revenue was $186.00 K,
an increase of 82.35% from the previous year.
In 2024, Celyad Oncology S.A.'s net income was -$5.82 M.
See Celyad Oncology S.A.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$186.00 K |
$102.00 K |
$0.00 |
$0.00 |
$5.00 K |
$6.00 K |
$3.12 M |
$3.54 M |
$10.01 M |
$3.00 K |
| Cost of Revenue |
$12.00 K
|
$69.00 K
|
$1.44 M
|
$1.52 M
|
$0.00
|
$0.00
|
$0.00
|
$515.00 K
|
$1.54 M
|
$2.00 K
|
| Gross Profit |
$174.00 K
|
$33.00 K
|
-$1.44 M
|
-$1.52 M
|
$5.00 K
|
$6.00 K
|
$3.12 M
|
$3.03 M
|
$8.47 M
|
$1.00 K
|
| Gross Profit Ratio |
0.94
|
0.32
|
0
|
0
|
1
|
1
|
1
|
0.85
|
0.85
|
0.33
|
| Research and Development Expenses |
$3.31 M
|
$4.67 M
|
$18.93 M
|
$20.77 M
|
$21.59 M
|
$25.23 M
|
$23.58 M
|
$22.91 M
|
$27.68 M
|
$22.77 M
|
| General & Administrative Expenses |
$3.09 M
|
$5.71 M
|
$10.34 M
|
$9.67 M
|
$9.32 M
|
$8.73 M
|
$9.01 M
|
$9.31 M
|
$9.74 M
|
$7.23 M
|
| Selling & Marketing Expenses |
$78.00 K
|
$215.00 K
|
$239.00 K
|
$434.00 K
|
$0.00
|
$0.00
|
$676.00 K
|
$761.00 K
|
$728.00 K
|
$0.00
|
| Selling, General & Administrative Expenses |
$3.20 M
|
$6.25 M
|
$10.56 M
|
$10.00 M
|
$9.32 M
|
$8.73 M
|
$9.68 M
|
$9.08 M
|
$9.57 M
|
$7.23 M
|
| Other Expenses |
-$479.00 K
|
-$2.43 M
|
-$9.00 M
|
-$3.53 M
|
-$4.34 M
|
-$4.58 M
|
$7.32 M
|
$23.68 M
|
-$2.52 M
|
-$222.00 K
|
| Operating Expenses |
$6.03 M
|
$8.49 M
|
$20.26 M
|
$26.91 M
|
$26.24 M
|
$29.38 M
|
$41.29 M
|
$55.90 M
|
$34.08 M
|
$29.68 M
|
| Cost And Expenses |
$6.04 M
|
$8.56 M
|
$20.26 M
|
$26.91 M
|
$26.24 M
|
$29.38 M
|
$41.29 M
|
$56.42 M
|
$35.62 M
|
$29.68 M
|
| Interest Income |
$34.00 K
|
$30.00 K
|
$12.00 K
|
$27.00 K
|
$217.00 K
|
$582.00 K
|
$804.00 K
|
$933.00 K
|
$1.41 M
|
$542.00 K
|
| Interest Expense |
$0.00
|
$84.00 K
|
$197.00 K
|
$255.00 K
|
$434.00 K
|
$343.00 K
|
$62.00 K
|
$144.00 K
|
$109.00 K
|
$236.00 K
|
| Depreciation & Amortization |
$183.00 K
|
$794.00 K
|
$1.44 M
|
$1.52 M
|
$1.83 M
|
$1.79 M
|
$1.11 M
|
$1.71 M
|
$1.52 M
|
$1.03 M
|
| EBITDA |
-$5.69 M |
-$7.76 M |
-$39.70 M |
-$25.41 M |
-$14.94 M |
-$26.51 M |
-$36.25 M |
-$55.70 M |
-$21.99 M |
-$28.07 M |
| EBITDA Ratio |
-30.58
|
-76.11
|
0
|
0
|
-2987.6
|
-4418.17
|
-11.64
|
-15.73
|
-2.2
|
-9357
|
| Operating Income Ratio |
-31.49
|
-82.91
|
0
|
0
|
-3397.4
|
-4813.17
|
-12.25
|
-14.94
|
-2.56
|
-9890.67
|
| Total Other Income/Expenses Net |
$34.00 K
|
-$182.00 K
|
-$13.00 K
|
-$111.00 K
|
-$217.00 K
|
$239.00 K
|
$743.00 K
|
-$3.52 M
|
$2.00 M
|
$558.00 K
|
| Income Before Tax |
-$5.82 M
|
-$8.64 M
|
-$40.87 M
|
-$26.50 M
|
-$17.20 M
|
-$28.64 M
|
-$37.43 M
|
-$56.40 M
|
-$23.61 M
|
-$29.11 M
|
| Income Before Tax Ratio |
-31.31
|
-84.7
|
0
|
0
|
-3440.8
|
-4773.33
|
-12.02
|
-15.93
|
-2.36
|
-9704.67
|
| Income Tax Expense |
$0.00
|
-$191.00 K
|
$65.00 K
|
$10.00 K
|
$0.00
|
-$8.00 K
|
$0.00
|
-$1.00 K
|
-$6.00 K
|
-$55.00 K
|
| Net Income |
-$5.82 M
|
-$8.45 M
|
-$40.94 M
|
-$26.51 M
|
-$17.50 M
|
-$28.63 M
|
-$37.43 M
|
-$56.40 M
|
-$23.61 M
|
-$29.11 M
|
| Net Income Ratio |
-31.31
|
-82.82
|
0
|
0
|
-3500.2
|
-4772
|
-12.02
|
-15.93
|
-2.36
|
-9704.67
|
| EPS |
-0.14 |
-0.33 |
-1.81 |
-1.7 |
-1.26 |
-2.29 |
-3.26 |
-5.86 |
-2.53 |
-3.43 |
| EPS Diluted |
-0.14 |
-0.33 |
-1.81 |
-1.7 |
-1.26 |
-2.29 |
-3.26 |
-5.86 |
-2.53 |
-3.43 |
| Weighted Average Shares Out |
$41.43 M
|
$25.72 M
|
$22.59 M
|
$15.60 M
|
$13.94 M
|
$12.52 M
|
$11.14 M
|
$9.62 M
|
$9.31 M
|
$8.48 M
|
| Weighted Average Shares Out Diluted |
$41.43 M
|
$25.72 M
|
$22.59 M
|
$15.60 M
|
$13.94 M
|
$12.52 M
|
$11.14 M
|
$9.62 M
|
$9.33 M
|
$8.49 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
